Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review
Authors' conclusion
HZ was the most common OI reported among RA patients using all currently approved JAK inhibitors in clinical trials, although tuberculosis and other OIs were also reported.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials105 publications · 62 trials
- Outcome
- Rates of opportunistic infections (OIs) associated with JAKi treatment for RA
Methodological detailsnarrative synthesis, MEDLINE and Embase searches through March 2021, gray literature searches
- Narrative synthesis
- MEDLINE and Embase searches through March 2021
- Gray literature searches
Main finding
As reported in the abstract
Opportunistic infections with JAKi in RA clinical trials
- Highest exposure-adjusted incidence rate for herpes zoster (any form), followed by OI (any) and tuberculosis, based on limited data from trials with approved doses
- Higher rates of opportunistic infections (OIs) in Asian and Australian populations vs the global population
- Higher rates of OIs with increasing JAKi dose in most clinical trial data
- Lack of head-to-head trials and differences in trial design preclude direct comparison across JAKi
Original publication
Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review. Semin Arthritis Rheum. Published 29 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →